Literature DB >> 380458

Cefamandole therapy in anaerobic infections.

R N Greenberg, M C Scalcini, C V Sanders, A C Lewis.   

Abstract

Thirty-one adult patients with infections due to anaerobic bacteria were treated with cefamandole. Bacteroides fragilis group (17) and Bacteroides melaninogenicus (13) were the most frequent anaerobes isolated. Duration of therapy varied from 2 to 49 days. Results were judged satisfactory in 26 cases, and unsatisfactory in 1 case. Four cases could not be evaluated. Adverse reactions occurred in 16 patients and included positive direct Coombs' test without hemolysis, transient liver function abnormalities, phlebitis, reversible neutropenia, fever, eosinophilia, and toxic epidermal necrolysis. The more significant reactions were associated with prolonged therapy. None was lethal. These data suggest that cefamandole is effective in treatment of most anaerobic infections.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 380458      PMCID: PMC352661          DOI: 10.1128/AAC.15.3.337

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  TOXIC EPIDERMAL NECROLYSIS (LYELL). THE SCALDED SKIN SYNDROME.

Authors:  F G ZAK; M J FELLNER; A J GELLER
Journal:  Am J Med       Date:  1964-07       Impact factor: 4.965

2.  THE ROLE OF SUTURE MATERIAL ON TUMOR IMPLANTATION.

Authors:  F C DIVINCENTI; I COHN
Journal:  JAMA       Date:  1965-01-11       Impact factor: 56.272

3.  Modification of the Minitek Miniaturized Differentiation System for characterization of anaerobic bacteria.

Authors:  D Stargel; F S Thompson; S E Phillips; G L Lombard; V R Dowell
Journal:  J Clin Microbiol       Date:  1976-03       Impact factor: 5.948

4.  Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria.

Authors:  E C Ernst; S Berger; M Barza; N V Jacobus; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

5.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

6.  Observations in man on some pharmacologic features of cefamandole.

Authors:  W E Grose; G P Bodey; D Stewart
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

7.  Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds.

Authors:  H C Neu
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

8.  Antibacterial activity of cefamandole in vitro.

Authors:  B R Meyers; S Z Hirschman
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

9.  Cefamandole in treatment of peritonitis.

Authors:  H H Stone; B S Guest; C E Geheber; L D Kolb
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

10.  Cefamandole---a review of chemistry and microbiology.

Authors:  G V Kaiser; M Gorman; J A Webber
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

View more
  4 in total

1.  Bacteroides fragilis septicemia during cefamandole therapy.

Authors:  J Righter
Journal:  Can Med Assoc J       Date:  1981-09-01       Impact factor: 8.262

2.  N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria.

Authors:  D A Martin; C V Sanders; R L Marier
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

3.  Pharmacology, Safety, and efficacy of cefamandole in childhood infections.

Authors:  M C Thirumoorthi; A S Dajani; C V Vincent; M J Maurer
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

4.  Moxalactam in the therapy of serious infections.

Authors:  R L Marier; S Faro; C V Sanders; W Williams; F Derks; A Janney; K Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.